The risk of hand foot skin reaction to pazopanib, a novel multikinase inhibitor: a systematic review of literature and meta-analysis. (Q37851857)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21394443%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

0 references

1 reference

title

The risk of hand foot skin reaction to pazopanib, a novel multikinase inhibitor: a systematic review of literature and meta-analysis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21394443%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

0 references

1 reference

ChEBI release 2020-05-28

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21394443%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

Mario E Lacouture

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21394443%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

author name string

Yevgeniy Balagula

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21394443%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

Shenhong Wu

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21394443%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

Xiao Su

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21394443%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

publication date

11 March 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21394443%20AND%20SRC:MED&resulttype=core&format=json

Investigational New Drugs

25 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21394443%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

volume

30

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21394443%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21394443%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

page(s)

1773-1781

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21394443%20AND%20SRC:MED&resulttype=core&format=json

BAY 43-9006 inhibition of oncogenic RET mutants

25 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9652-2

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9652-2

Sunitinib in solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9652-2

Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9652-2

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9652-2

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9652-2

Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9652-2

Risk of hand-foot skin reaction with the multitargeted kinase inhibitor sunitinib in patients with renal cell and non-renal cell carcinoma: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9652-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9652-2

Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9652-2

Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9652-2

Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9652-2

A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9652-2

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9652-2

Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC stu

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9652-2

Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9652-2

Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9652-2

Phase II proof-of-concept study of pazopanib monotherapy in treatment-naive patients with stage I/II resectable non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9652-2

A phase II study of pazopanib in patients with recurrent or metastatic invasive breast carcinoma: a trial of the Princess Margaret Hospital phase II consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9652-2

Uncovering Pandora's vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9652-2

Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9652-2

Lack of association between excretion of sorafenib in sweat and hand-foot skin reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9652-2

Epithelial-stromal interactions in basal cell cancer: the PDGF system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9652-2

Reduction in skin microvascular density and changes in vessel morphology in patients treated with sunitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9652-2

Application of a PDGF-containing novel gel for cutaneous wound healing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9652-2

Effect of axitinib (AG-013736) on fatigue, thyroid-stimulating hormone, and biomarkers: a phase I study in Japanese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9652-2

Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9652-2

Vandetanib, designed to inhibit VEGFR2 and EGFR signaling, had no clinical activity as monotherapy for recurrent ovarian cancer and no detectable modulation of VEGFR2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9652-2

Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9652-2

Cutaneous side-effects of kinase inhibitors and blocking antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9652-2

Sunitinib: from rational design to clinical efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9652-2

Targeted therapy and hand-foot skin reaction in advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9652-2

Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9652-2

Sorafenib and sunitinib: novel targeted therapies for renal cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9652-2

Expression of c-kit and kit ligand proteins in normal human tissues

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21394443

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21394443

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S10637-011-9652-2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21394443%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

1 reference